Chemkart India Ltd
Incorporated in 2020, Chemkart India Limited, based in Mumbai, is a B2B nutraceutical ingredient distributor and processor.[1]
- Market Cap ₹ 143 Cr.
- Current Price ₹ 118
- High / Low ₹ 262 / 104
- Stock P/E 7.49
- Book Value ₹ 100
- Dividend Yield 0.00 %
- ROCE 61.5 %
- ROE 59.0 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 1.18 times its book value
- Company has a good return on equity (ROE) track record: 3 Years ROE 63.1%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Fast Moving Consumer Goods Fast Moving Consumer Goods Food Products Other Food Products
Part of BSE SME IPO
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|
| 87 | 131 | 132 | 203 | 193 | |
| 80 | 120 | 111 | 171 | 167 | |
| Operating Profit | 7 | 11 | 21 | 33 | 27 |
| OPM % | 8% | 8% | 16% | 16% | 14% |
| 0 | 0 | 1 | 2 | 1 | |
| Interest | 0 | 1 | 1 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 1 | 1 |
| Profit before tax | 7 | 11 | 20 | 33 | 26 |
| Tax % | 25% | 27% | 27% | 26% | |
| 5 | 8 | 15 | 24 | 19 | |
| EPS in Rs | 40.38 | 56.45 | 107.00 | 25.55 | 17.76 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 33% |
| TTM: | 54% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 64% |
| TTM: | 67% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 63% |
| Last Year: | 59% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 10 | 12 |
| Reserves | 5 | 13 | 28 | 44 | 109 |
| 6 | 11 | 13 | 17 | 1 | |
| 12 | 12 | 12 | 16 | 15 | |
| Total Liabilities | 25 | 37 | 54 | 86 | 137 |
| 1 | 6 | 5 | 9 | 9 | |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| 24 | 32 | 48 | 77 | 128 | |
| Total Assets | 25 | 37 | 54 | 86 | 137 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| -6 | 0 | -0 | 4 | |
| -1 | -5 | -0 | -4 | |
| 7 | 5 | 0 | 3 | |
| Net Cash Flow | -0 | 0 | -0 | 3 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 80 | 62 | 87 | 82 |
| Inventory Days | 9 | 25 | 27 | 50 |
| Days Payable | 41 | 34 | 33 | 23 |
| Cash Conversion Cycle | 49 | 53 | 81 | 109 |
| Working Capital Days | 28 | 25 | 66 | 75 |
| ROCE % | 58% | 63% | 62% |
Documents
Announcements
-
Submission Of Disclosure Of Related Party Transactions Under Regulation 23(9) Read With Regulation 15 Of SEBI (LODR) Regulations, 2015
13 Jan - Filed RPTs for half-year ended 30 Sep 2025; paid BSE penalty INR 11,800 on 30-Dec-2025.
-
Announcement under Regulation 30 (LODR)-Acquisition
13 Jan - Invested Rs.1.50 crore via allotment of 15,00,000 shares in wholly-owned subsidiary on Jan 13, 2026.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
12 Jan - Certificate: Reg 74(5) not applicable—all shares in demat, no remat requests for quarter ended 31 Dec 2025.
-
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
26 Dec - Promoter Shailesh Mehta acquired 6,600 shares (0.054%) on 22 and 23 Dec 2025 via open market.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
16 Dec 2025 - DRI investigating import classification; INR15.72Cr duty assessed, INR12.78Cr paid, INR2.94Cr to be settled within seven days.
Annual reports
No data available.
Business Segment[1]
a) Trading Business:(97% of H1FY25 revenue)[2]
The company sources a wide range of nutraceutical ingredients—such as amino acids, vitamins, herbal extracts, and proteins—mainly through imports, and supplies them to B2B clients for manufacturing finished supplements.